drugset / Trial / NCT05908747
Efficacy and Safety of Surufatinib Combined With Gemcitabine and Albumin-bound Paclitaxel in the Peri-operative Treatment of Pancreatic Cancer
NaSingle-groupOpen-labelTreatment
Summary
This study is designed to explore the efficacy and safety of surufatinib combined with gemcitabine and nab-paclitaxel as peri-operative treatment in locally advanced or borderline resectable pancreatic cancer.
Timeline
- Start
- 2023-05-31
- Primary completion
- 2025-05-16
- Completion
- 2026-06-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gemcitabine | Small molecule | 1000 mg/m2 | — |
| Subject | Paclitaxel | Small molecule | 125 mg/m2 | Intravenous |
| Subject | Surufatinib | Small molecule | 250 mg | Oral |